不可切除肝细胞癌新型联合策略的疗效比较:III期试验的网络荟萃分析
该网络荟萃分析纳入9项III期随机对照试验,比较不可切除肝细胞癌一线治疗方案的OS和PFS;阿替利珠单抗联合贝伐珠单抗较安慰剂、索拉非尼、仑伐替尼、阿替利珠单抗联合卡博替尼、纳武利尤单抗和多纳非尼降低死亡风险,但与度伐利尤单抗联合替西木单抗及信迪利单抗联合IBI305相比无统计学显著差异。
要点
- 阿替利珠单抗联合贝伐珠单抗较索拉非尼降低死亡风险(HR 0.58;95% CI 0.42-0.80)。
- 阿替利珠单抗联合贝伐珠单抗较仑伐替尼降低死亡风险(HR 0.63;95% CI 0.44-0.89)。
- 疗效与更高的3级不良事件风险相关。
核心结论
- 阿替利珠单抗联合贝伐珠单抗较多个对照方案降低死亡风险,但与度伐利尤单抗联合替西木单抗及信迪利单抗联合IBI305相比未达统计学显著优势。
研究设计与样本
- 系统检索MEDLINE、Cochrane图书馆和Embase(2007年1月至2022年2月),纳入9项III期随机对照试验,采用固定效应多变量meta回归模型进行频率学网络荟萃分析。
主要发现
- 阿替利珠单抗联合贝伐珠单抗较安慰剂降低死亡风险(HR 0.40;95% CI 0.28-0.57)。
- 阿替利珠单抗联合贝伐珠单抗较索拉非尼降低死亡风险(HR 0.58;95% CI 0.42-0.80)。
- 阿替利珠单抗联合贝伐珠单抗较仑伐替尼降低死亡风险(HR 0.63;95% CI 0.44-0.89)。
- 阿替利珠单抗联合贝伐珠单抗较阿替利珠单抗联合卡博替尼降低死亡风险(HR 0.64;95% CI 0.43-0.97)。
- 阿替利珠单抗联合贝伐珠单抗较纳武利尤单抗降低死亡风险(HR 0.68;95% CI 0.48-0.98)。
关键数值与推荐
- 阿替利珠单抗联合贝伐珠单抗 vs 安慰剂:HR 0.40(95% CI 0.28-0.57)。
- 阿替利珠单抗联合贝伐珠单抗 vs 索拉非尼:HR 0.58(95% CI 0.42-0.80)。
- 阿替利珠单抗联合贝伐珠单抗 vs 仑伐替尼:HR 0.63(95% CI 0.44-0.89)。
- 阿替利珠单抗联合贝伐珠单抗 vs 阿替利珠单抗联合卡博替尼:HR 0.64(95% CI 0.43-0.97)。
- 阿替利珠单抗联合贝伐珠单抗 vs 纳武利尤单抗:HR 0.68(95% CI 0.48-0.98)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dual programmed cell death-1 and vascular endothelial growth factor pathway inhibition is the novel standard of care for patients with unresectable hepatocellular carcinoma. Direct comparisons between first-line treatments are lacking. METHOD: We conducted a literature search in MEDLINE (https://pubmed.ncbi.nlm.nih.gov), the Cochrane library (https://www.cochranelibrary.com) and Embase (www.embase.com) between January 2007 and February 2022. We included phase III randomised controlled trials that tested immune-checkpoint inhibitors or tyrosine kinase inhibitors, including sorafenib, lenvatinib and donafenib, and evaluated as primary end-point overall survival (OS) or progression-free survival (PFS). Studies testing loco-regional therapies were excluded. The primary end-point was to compare the efficacy of first-line options in terms of OS and PFS. We extracted Hazard ratios (HR) and 95% confidence intervals (95% CI) for OS and PFS and performed a frequentist network meta-analysis with fixed effect multivariable meta-regression models. The research protocol was registered in PROSPERO, an international prospective register of systematic reviews (registration code CRD42022312489). FINDINGS: Literature review yielded 13709 results, after duplicates removal and exclusion of not relevant studies, 70 papers were available for screening. After full-text review, 9 studies were eligible for analysis. Atezolizumab plus bevacizumab reduced the risk of death compared to placebo (HR 0·40; 95% CI 0·28-0·57), sorafenib (HR 0·58; 95% CI 0·42-0·80), lenvatinib (HR 0·63; 95% CI 0·44-0·89), atezolizumab plus cabozantinib (HR 0·64; 95% CI 0·43-0·97), nivolumab (HR 0·68; 95% CI 0·48-0·98) and donafenib (HR 0·69; 95% CI 0·48-0·99). Atezolizumab plus bevacizumab was not statistically superior to durvalumab plus tremelimumab (HR 0·74; 95% CI 0·52-1·06) and sintilimab plus IBI305 (HR 1·02; 95% CI 0·67-1·55) in reducing the risk of death. Efficacy was associated with a higher risk of grade 3 adverse events.
引用
- Fulgenzi CAM, D'Alessio A, Airoldi C, et al. Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials. Eur J Cancer. 2022. PMID: 35970037. doi:10.1016/j.ejca.2022.06.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。